SNYR
Synergy CHC Corp.
Next earnings Aug 12, 2026 · consensus $0.09 EPS, $11.7M rev
Last earnings -8.3% on 2026-05-14
$0.21
▲ +1.47%$0.21▼ -92.74%
over 1Y
L $0.19H $3.97
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.5%
1W+2.0%
1M-22.8%
3M-74.1%
YTD-89.0%
1Y-92.7%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 8 analysts
Buy
Insolvent micro-cap: negative equity, shrinking sales, related-party write-offs and $25M debt make SNYR a speculation, not an investment.
Revenue $30.4M · FY2025
SNYR is a $2.3M-market-cap nutraceutical shell (FOCUSfactor, Flat Tummy) whose FY2025 results mark a decisive break from the two prior profitable years. Revenue fell 12.8% to $30.4M and the company swung from +$2.1M net income in 2024 to a -$12.3M loss, driven by a collapse in operating income to -$8.46M and $5.9M of interest expense. The 67% gross margin is genuinely healthy for the category, but everything below the gross line is broken: G&A nearly doubled to $8.8M and a $6.66M bad-debt reserve appeared out of nowhere. Critically, $4.4M of that reserve is the write-off of a *related-party* loan receivable — a governance red flag that says as much about how this company is run as the P&L does.
The balance sheet is the disqualifier. Stockholders' equity is -$23.1M against total liabilities of $33.3M, with long-term debt up 236% to $25.1M and only $2.62M of cash. This company is technically insolvent, and its accumulated deficit of -$56.4M against 30-year revenue confirms it has never durably created value. Operating cash flow is negative (-$2.59M), so the debt load is not self-funding. The one-time 'gain on settlement of notes payable' ($2.15M) and the licensing episode — where $2.9M of FOCUSfactor/Flat Tummy license revenue was booked in H1 2025 then fully *reversed* in Q4 when the licensee canceled — show earnings quality is essentially unknowable quarter to quarter.
Is SNYR a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~90d expiry
- Long put 0 @ ~0.00 est
- Short put 0 @ ~0.00 est
debit $0max +$0max $0
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY18 | FY19 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $33.8M | — | $42.8M | $34.8M | $30.4M |
| Gross profit | $22.8M | $20.2M | $32.1M | $23.6M | $20.3M |
| Operating income | -$4.92M | -$7.96M | $10.8M | $5.80M | -$8.46M |
| Net income | -$6.16M | -$9.21M | $6.34M | $2.12M | -$12.3M |
| Diluted EPS | -$0.07 | -$0.10 | $0.86 | $0.28 | -$1.27 |
| Net margin | -18.2% | — | 14.8% | 6.1% | -40.6% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$29.5M
EV / EBITDA—
EV / Sales1.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-400.1%
FCF yield-88.0%
Quality & risk
ROIC (est.)—
Free cash flow-$2.71M
Total debt$29.1M
Net cash-$26.4M
Altman Z-Score-7.27 distress
Piotroski F-Score3/9
Capital returns
Buyback yield—
Dividend yield (est.)38.1%
Shareholder yield38.1%
Shares Δ YoY+29.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Officer / director change2026-06-29
Annual meeting vote results filed alongside a board/officer change
- 8-K Delisting notice2026-05-18
Received notice of failure to meet a continued-listing (delisting) standard
- S-1 Securities registration2026-05-15
Filed S-1 to register shares — potential dilution overhang
- 8-K Earnings results2026-05-14
Q1 2026: losses continue, negative equity persists
- 10-Q Quarterly report2026-05-14
Q1 2026: losses continue, negative equity persists
- 8-K Material agreement2026-05-11
Entered a new material definitive agreement
- DEF 14A Proxy statement2026-04-30
Proxy for annual meeting — routine director/governance votes
- 10-K Annual report2026-04-01
Filed late-filing notice for the FY25 annual report
- NT 10-K Late filing notice2026-04-01
Filed late-filing notice for the FY25 annual report
Recent filings
all on EDGAR ↗4Period ending 2026-06-292026-07-01open ↗4Period ending 2026-06-292026-07-01open ↗4Period ending 2026-06-292026-07-01open ↗8-KPeriod ending 2026-06-292026-06-29open ↗EFFECTFiling2026-05-22open ↗8-KPeriod ending 2026-05-152026-05-18open ↗S-1Filing2026-05-15open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-082026-05-11open ↗ARSPeriod ending 2025-12-312026-04-30open ↗DEFA14AFiling2026-04-30open ↗
Frequently asked
- Is Synergy CHC Corp. (SNYR) a buy?
- SNYR currently carries a Avoid rating with 5/5 conviction, derived from its latest SEC filings. Insolvent micro-cap: negative equity, shrinking sales, related-party write-offs and $25M debt make SNYR a speculation, not an investment.
- What is Synergy CHC Corp.'s quality score?
- SNYR scores 33.77609973410459/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001562733, latest 10-Q filed 2026-05-14) · EODHD · Proprietary analysis · as of 7/4/2026, 10:23:15 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:23 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.